Company
Peloton Therapeutics
Translating Novel Scientific Insights Into First-In-Class Medicines
Also known as Peloton Therapeutics, Inc
- Status
- Acquiredas of 2026-09-18Source (opens in a new tab)
- Business model
- B2B
- Legal name
- Peloton Therapeutics, Inc
Claim, correct or request removal
Record updated 29 September 2026
About
Peloton Therapeutics, Inc. is a clinical stage pharmaceutical company focused on translating novel scientific insights into first-in-class medicines for patients with cancer and other debilitating or life-threatening conditions.
Funding snapshot
- Total raised
- $11.7MSEC form D sum, as of 2026-09-29Source (opens in a new tab)
- Latest round
- Round, $11.7M2011-06-30
Funding rounds
- Round, 2011
- $11.7M2011-06-30, SEC form D sold, 4 investors
About the company
- Status notes
- Peloton was acquired by Merck in May 2019 for up to $2.35B.
Exit
- Acquisition
- $2.4B, 2019-05up to $2.35B
Loading relationship preview